


## WHAT IS CLAIMED IS:

1. A compound represented by Formula (I):



(I)

5

or a pharmaceutically acceptable salt thereof, wherein

A is C or N;

X is phenyl, pyridyl, pyrazinyl, thiaphenyl, quinolinyl, benzofuranyl, oxadiazolyl, diazolyldipyrindyl, imidazolylpyridinyl, oxadiazolylphenyl, or

10 benzodioxolyl;

R<sub>1</sub> is hydrogen, halogen; or -C<sub>1</sub>-6alkyl, -cycloC<sub>3</sub>-6alkyl, or -C<sub>1</sub>-6alkenyl group, wherein any of the groups is optionally substituted with 1-6 substituents; wherein each substituent is independently halogen, -OH, -CN, or -SO<sub>2</sub>-C<sub>1</sub>-6alkyl;

15

R<sub>2</sub>, and R<sub>3</sub> are each independently hydrogen, halogen, hydroxyl, -CN, -NO<sub>2</sub>; or -C<sub>1</sub>-6alkyl, -C<sub>2</sub>-6alkenyl, -C<sub>1</sub>-6alkyl(C<sub>2</sub>-6alkenyl)<sub>2</sub>, -C<sub>0</sub>-4alkyl(C<sub>3</sub>-6cycloalkyl)<sub>2</sub>, -C<sub>0</sub>-6alkyl-N(C<sub>0</sub>-6alkyl)<sub>2</sub>, -C<sub>0</sub>-4alkyl-O-C<sub>1</sub>-6alkyl, -C<sub>1</sub>-6alkyl-phenyl, -C<sub>0</sub>-6alkyl-SO<sub>2</sub>-C<sub>1</sub>-6alkyl, -C<sub>0</sub>-6alkyl-C(O)-C<sub>0</sub>-4alkyl, -C<sub>0</sub>-6alkyl-C(O)-C<sub>0</sub>-6alkyl-phenyl, -C<sub>0</sub>-6alkyl-C(O)-C<sub>0</sub>-4alkyl-O-C<sub>0</sub>-6alkyl, -C<sub>0</sub>-6alkyl-C(O)-C<sub>0</sub>-6alkyl-O-C<sub>0</sub>-6alkyl-O-C<sub>0</sub>-6alkyl-C(O)-C<sub>0</sub>-6alkyl, -C<sub>2</sub>-6alkenyl-C(O)-C<sub>0</sub>-4alkyl-O-C<sub>0</sub>-6alkyl, -C<sub>0</sub>-4alkyl-C<sub>3</sub>-6cycloalkyl-C<sub>0</sub>-6alkyl-C(O)-C<sub>0</sub>-6alkyl, -C<sub>0</sub>-4alkyl-C<sub>3</sub>-6cycloalkyl-C<sub>0</sub>-6alkyl-C(O)-C<sub>0</sub>-6alkyl-N(C<sub>0</sub>-6alkyl)<sub>2</sub>, -C<sub>0</sub>-4alkyl-C<sub>3</sub>-6cycloalkyl-C<sub>0</sub>-6alkyl-C(O)-C<sub>0</sub>-4alkyl-O-C<sub>0</sub>-6alkyl, -C<sub>2</sub>-6alkenyl-C(O)-C<sub>0</sub>-4alkyl-N(C<sub>0</sub>-6alkyl)-pyridyl, -C<sub>0</sub>-6alkyl-C(O)-C<sub>0</sub>-4alkyl-N(C<sub>0</sub>-4alkyl)<sub>2</sub>, -C<sub>0</sub>-6alkyl-C(O)-C<sub>0</sub>-4alkyl-N(C<sub>0</sub>-4alkyl)-C<sub>3</sub>-6cycloalkyl, -C<sub>2</sub>-6alkenyl-C(O)-C<sub>0</sub>-4alkyl-N(C<sub>0</sub>-4alkyl)-C<sub>3</sub>-6cycloalkyl, -SO<sub>2</sub>-C<sub>0</sub>-6alkyl-phenyl, -SO<sub>2</sub>-C<sub>0</sub>-6alkyl-(C<sub>0</sub>-6alkyl-phenyl)-(C<sub>0</sub>-6alkyl-phenyl), -C<sub>0</sub>-4alkyl-SO<sub>2</sub>-C<sub>0</sub>-4alkyl-C<sub>3</sub>-

20

25

6cycloalkyl-C0-4alkyl-C(O)-C0-4alkyl-O-C0-4alkyl, -S(O)-C0-6alkyl, -P(O)(O-C0-4alkyl)(O-C0-4alkyl), -C2-6alkenyl-C(O)-C0-4alkyl-N(C0-4alkyl)-pyridyl, -S-C1-6alkyl, -C0-6alkyl-N(C0-6alkyl)-C(O)-C0-6alkyl, -C0-6alkyl-N(C0-6alkyl)-C(O)-N(C0-6alkyl)2, -C0-4alkyl-S-C1-4alkyl-oxadiazolyl(C0-4alkyl), -C0-4alkyl-C(O)-C0-4alkyl-phenyl, -C0-4alkyl-O-C0-4alkyl-phenyl, -C0-4alkyl-C3-6cycloalkyl-C0-4alkyl-tetrazolyl, -SO2-N(C0-4alkyl)2, -C0-4alkyl-S-C0-4alkyl-thiadiazolyl(C0-4alkyl), -C0-4alkyl-S-C0-4alkyl-diazolyl(C0-4alkyl), -C0-4alkyl-S-C1-4alkyl-Si(C0-4alkyl)3, -C0-4alkyl-S-C0-4alkyl-phenyl(C0-4alkyl), -C0-4alkyl-S-C0-4alkyl-C(O)-C0-4alkyl-O-C0-4alkyl, or -C0-4alkyl-S-C0-4alkyl-C3-6cycloalkyl-C0-4alkyl-C(O)-C0-4alkyl-O-C0-4alkyl, wherein any alkyl, cycloalkyl, alkenyl, phenyl, or pyridyl are each optionally substituted with 1-9 independently halogen, hydroxyl, -C0-4alkyl-O-C1-6alkyl, or -C0-4alkyl-S-C1-6alkyl; optionally, R2 forms =O with an adjoining bond; R4 is hydrogen, or halogen; and any ring nitrogen optionally forms *N*-oxide or *N*-chloride.

2. The compound according to claim 1, wherein A is C.
3. The compound according to claim 2, wherein X is phenyl.
4. The compound according to claim 2, wherein X is thiaphenyl.
5. The compound according to claim 2, wherein X is benzofuranyl.
6. The compound according to claim 2, wherein X is pyridyl.
7. The compound according to claim 2, wherein X is pyridyl and
8. The compound according to claim 2, wherein X is quinoliny.
9. The compound according to claim 2, wherein X is oxadiazolyl.
10. The compound according to claim 2, wherein X is diazolyipyridinyl or imidazolyipyridinyl.

11. The compound according to claim 2, wherein X is pyrazinyl.

12. The compound according to claim 2, wherein X is  
5 oxadiazolylphenyl.


13. The compound according to claim 2, wherein X is benzodioxolyl.


10 14. The compound according to claim 1, wherein A is N.

15. The compound according to claim 14, wherein X is phenyl.

15


16. The compound according to claim 1, represented by





or a pharmaceutically acceptable salt thereof.


17. The compound according to claim 1, represented by




5

or a pharmaceutically acceptable salt thereof.

18. The compound according to claim 1, represented by





or a pharmaceutically acceptable salt thereof.

19. The compound according to claim 1, selected from the group consisting of
- 5 6-isopropyl-8-(4'-methanesulfonyl-biphenyl-3-yl)-quinoline;
  - 1-(3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-3-yl)-ethanone;
  - 1-(3-hydroxy-3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-4-yl)-ethanone;
  - 10 1-(4-hydroxy-3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-3-yl)-ethanone;
  - 8-(3'-methanesulfonyl-biphenyl-3-yl)-6-(1-methanesulfonyl-1-methyl-ethyl)-quinoline;
  - 8-(4'-methanesulfonyl-biphenyl-3-yl)-6-(1-methanesulfonyl-1-methyl-ethyl)-quinoline;
  - 15 3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-4-carbonitrile;
  - 6-(1-methanesulfonyl-1-methyl-ethyl)-8-(3'-nitro-biphenyl-3-yl)-quinoline;
  - 20 {4-chloro-3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-3-yl}-methanol;
  - 3-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-3-yl}-acrylic acid methyl ester;
  - 3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-3-carbaldehyde;
  - 25 2,2,2-trifluoro-1-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-3-yl}-ethanol;
  - {3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-2-yl}-methanol;
  - 30 3-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-2-yl}-acrylic acid methyl ester;
  - 8-(2'-methanesulfonylmethyl-biphenyl-3-yl)-6-(1-methanesulfonyl-1-methyl-ethyl)-quinoline;
  - 6-(1-methanesulfonyl-1-methyl-ethyl)-8-[2'-([1,3,4]thiadiazol-2-yl)sulfanylmethyl]-biphenyl-3-yl]-quinoline;
  - 35



- {3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-4-yl}-methanol;
- 3-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-4-yl}-acrylic acid methyl ester;
- 5 6-(1-methanesulfonyl-1-methyl-ethyl)-8-[2'-(1-methyl-1H-imidazol-2-yl)sulfanylmethyl]-biphenyl-3-yl]-quinoline;
- 3-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-2-yl}-propionic acid methyl;
- 3-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-2-yl}-prop-2-en-1-ol;
- 10 3-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-2-yl}-propan-1-ol;
- {3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-3-yl}-methanol;
- 15 3-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-2-yl}-propionic acid;
- 3-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-3-yl}-acrylic acid;
- 3-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-3-yl}-propionic acid;
- 20 3-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-4-yl}-acrylic acid;
- 3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-2-carbonitrile;
- 25 6-(1-methanesulfonyl-1-methyl-ethyl)-8-(2'-methylsulfanyl-biphenyl-3-yl)-quinoline;
- 8-(2'-methanesulfonyl-biphenyl-3-yl)-6-(1-methanesulfonyl-1-methyl-ethyl)-quinoline;
- {3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-3-yl}-acetic acid;
- 30 3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-3-carboxylic acid;
- 3-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-4-yl}-propionic acid methyl ester;

- 3-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-4-yl}-propionic acid;
- 2-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid methyl ester;
- 5 3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-3-carboxylic acid amide;
- 2-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-3-yl}-cyclopropanecarboxylic acid;
- 3-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-4-yl}-2-methyl-propionic acid tert-butyl ester;
- 10 3-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-4-yl}-2-methyl-propionic acid;
- 2-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-4-yl}-2-methyl-propionic acid methyl ester;
- 15 {3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-4-yl}-acetic acid;
- 1-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid amide;
- 2-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-3-yl}-2-methyl-propionic acid;
- 20 (1-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-4-ylmethylsulfanylmethyl}-cyclopropyl)-acetic acid;
- (1-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-4-ylmethanesulfonyl-methyl}-cyclopropyl)-acetic acid;
- 25 3-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-4-yl}-acrylic acid methyl ester;
- 1-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-4-ylmethyl}-cyclobutanecarboxylic acid;
- 6-(1-methanesulfonyl-1-methyl-ethyl)-8-{4'-[2-(1H-tetrazol-5-yl)-cyclopropyl]-biphenyl-3-yl}-quinoline;
- 30 (1-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-4-ylsulfanylmethyl}-cyclopropyl)-acetic acid;
- (1-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-4-sulfonylmethyl}-cyclopropyl)-acetic acid;

3-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-4-yl}-acrylic acid;

or a pharmaceutically acceptable salt thereof.

5

20. The compound according to claim 1, consisting of

- 6-(1-methanesulfonyl-1-methyl-ethyl)-8-[3-(5-trifluoromethyl-pyridin-2-yl)-phenyl]-quinoline;
- 6-(1-methanesulfonyl-1-methyl-ethyl)-8-[3-(3-methyl-pyridin-2-yl)-phenyl]-quinoline;
- 6-(1-methanesulfonyl-1-methyl-ethyl)-8-(3-pyridin-3-yl-phenyl)-quinoline;
- 6-(1-methanesulfonyl-1-methyl-ethyl)-8-(3-pyridin-4-yl-phenyl)-quinoline;
- 6-(1-methanesulfonyl-1-methyl-ethyl)-8-[3-(5-methanesulfonyl-pyridin-3-yl)-phenyl]-quinoline;
- 6-(1-methanesulfonyl-1-methyl-ethyl)-8-[3-(6-methylsulfanyl-pyridin-2-yl)-phenyl]-quinoline;
- 6-(1-methanesulfonyl-1-methyl-ethyl)-8-[3-(6-methylsulfanyl-pyridin-3-yl)-phenyl]-quinoline;
- 2-(6-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-pyridin-3-yl)-propan-2-ol;
- 6-(1-methanesulfonyl-1-methyl-ethyl)-8-[3-(6-methyl-pyridin-3-yl)-phenyl]-quinoline;
- 5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-nicotinic acid ethyl ester;
- 6-(1-methanesulfonyl-1-methyl-ethyl)-8-{3-[6-(propane-2-sulfonyl)-pyridin-3-yl]-phenyl}-quinoline;
- 8-[3-(6-benzyloxy-pyridin-3-yl)-phenyl]-6-(1-methanesulfonyl-1-methyl-ethyl)-quinoline;
- 2-(5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-pyridin-3-yl)-propan-2-ol;
- 6-(1-methanesulfonyl-1-methyl-ethyl)-8-{3-[5-(2-trimethylsilanyl-ethylsulfanyl)-pyridin-3-yl]-phenyl}-quinoline;

- 8-{3-[5-(4-fluoro-benzylsulfanyl)-pyridin-3-yl]-phenyl}-6-(1-methanesulfonyl-1-methyl-ethyl)-quinoline;
- N-cyclopropyl-5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-nicotinamide;
- 5 3-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-5-trifluoromethyl-pyridin-2-ylamine;
- dicyclopropyl-(5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-1-oxy-pyridin-2-yl)-methanol;
- 8-[3-(6-ethanesulfonyl-pyridin-3-yl)-phenyl]-6-(1-methanesulfonyl-1-
- 10 methyl-ethyl)-quinoline;
- 2-(5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-pyridin-2-yl)-propan-2-ol;
- 6-(1-methanesulfonyl-1-methyl-ethyl)-8-{3-[1-oxy-5-(2-trimethylsilyl-ethanesulfonyl)-pyridin-3-yl]-phenyl}-quinoline;
- 15 8-(3-{5-[1,2-bis-(4-fluoro-phenyl)-ethanesulfonyl]-1-oxy-pyridin-3-yl}-phenyl)-6-(1-methanesulfonyl-1-methyl-ethyl)-quinoline;
- 8-[3-(5-ethanesulfonyl-1-oxy-pyridin-3-yl)-phenyl]-6-(1-methanesulfonyl-1-methyl-ethyl)-quinoline;
- 6-(1-methanesulfonyl-1-methyl-ethyl)-8-[3-(1-oxy-5-trifluoromethyl-
- 20 pyridin-3-yl)-phenyl]-quinoline;
- 6-(1-methanesulfonyl-1-methyl-ethyl)-8-[3-(6-methanesulfonyl-5-methyl-pyridin-3-yl)-phenyl]-quinoline;
- 3-(5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-1-oxy-pyridin-2-yl)-pentan-3-ol;
- 25 (5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-1-oxy-pyridin-3-yl)-methanol;
- difluoro-(5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-pyridin-3-ylsulfanyl)-acetic acid ethyl ester;
- difluoro-(5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-
- 30 phenyl}-pyridin-3-ylsulfanyl)-acetic acid;
- (5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-1-oxy-pyridin-2-yl)-methanol;
- 1-isopropyl-3-(5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-pyridin-2-yl)-urea;

- 6-(1-methanesulfonyl-1-methyl-ethyl)-8-{3-[5-(2-trimethylsilyl-ethanesulfonyl)-pyridin-3-yl]-phenyl}-quinoline;
- 8-[3-(4-chloro-pyridin-3-yl)-phenyl]-6-(1-methanesulfonyl-1-methyl-ethyl)-quinoline;
- 5 (5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-pyridin-2-yl)-(4-methylsulfanyl-phenyl)-methanone;
- 5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-1-oxy-pyridine-2-carboxylic acid isopropylamide;
- 1,1,1,3,3,3-hexafluoro-2-(5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-pyridin-3-yl)-propan-2-ol;
- 10 6-(1-methanesulfonyl-1-methyl-ethyl)-8-{3-[6-(4-methoxy-benzyloxy)-pyridin-2-yl]-phenyl}-quinoline;
- 1,1,1,3,3,3-hexafluoro-2-(5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-1-oxy-pyridin-3-yl)-propan-2-ol;
- 15 5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-nicotinic acid;
- 1,1,1,3,3,3-hexafluoro-2-(5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-1-oxy-pyridin-2-yl)-propan-2-ol;
- 5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-1-oxy-pyridine-2-carboxylic acid methyl ester;
- 20 5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-1-oxy-pyridine-2-carboxylic acid;
- 5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-1-oxy-nicotinic acid;
- 25 5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-1-oxy-nicotinonitrile;
- 5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-1-oxy-nicotinic acid 2,2-dimethyl-propionyloxymethyl ester;
- 8-[3-(5-chloro-1-oxy-pyridin-3-yl)-phenyl]-6-(1-methanesulfonyl-1-methyl-ethyl)-quinoline;
- 30 [1-(5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-pyridin-2-yl)sulfanylmethyl)-cyclopropyl]-acetic acid;
- [1-(5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-pyridine-2-sulfonylmethyl)-cyclopropyl]-acetic acid;

6-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-  
1H-pyridin-2-one

or a pharmaceutically acceptable salt thereof.

5

21. The compound according to claim 1, selected from the group  
consisting of

6-(1-methanesulfonyl-1-methyl-ethyl)-8-(3-thiophen-2-yl-phenyl)-  
quinoline;

10

1-(5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-  
thiophen-2-yl)-ethanone;

6-(1-methanesulfonyl-1-methyl-ethyl)-8-[3-(3-methyl-thiophen-2-yl)-  
phenyl]-quinoline;

15

5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-  
thiophene-2-sulfonic acid amide;

6-(1-methanesulfonyl-1-methyl-ethyl)-8-(3-quinolin-3-yl-phenyl)-  
quinoline;

20

8-(3-benzo[1,3]dioxol-5-yl-phenyl)-6-(1-methanesulfonyl-1-methyl-  
ethyl)-quinoline;

or a pharmaceutically acceptable salt thereof.

22. The compound according to claim 1, selected from the group  
consisting of

25

6-(1-methanesulfonyl-1-methyl-ethyl)-8-(5-phenyl-pyridin-3-yl)-  
quinoline;

6-(1-methanesulfonyl-1-methyl-ethyl)-8-(1-oxy-5-phenyl-pyridin-3-  
yl)-quinoline;

or a pharmaceutically acceptable salt thereof.

30

23. A pharmaceutical composition comprising:

a therapeutically effective amount of the compound according to any one  
of claims 1 to 22 or a pharmaceutically acceptable salt thereof; and  
a pharmaceutically acceptable carrier.

24. The pharmaceutical composition according to claim 23, further comprising a Leukotriene receptor antagonist, a Leukotriene biosynthesis inhibitor, or an M2/M3 antagonist.

5                   25. A method of treatment or prevention of asthma; chronic  
bronchitis; chronic obstructive pulmonary disease; adult respiratory distress  
syndrome; infant respiratory distress syndrome; cough; chronic obstructive pulmonary  
disease in animals; adult respiratory distress syndrome; ulcerative colitis; Crohn's  
disease; hypersecretion of gastric acid; bacterial, fungal or viral induced sepsis or  
10   septic shock; endotoxic shock; laminitis or colic in horses; spinal cord trauma; head  
injury; neurogenic inflammation; pain; reperfusion injury of the brain; psoriatic  
arthritis; rheumatoid arthritis; ankylosing spondylitis; osteoarthritis; inflammation; or  
cytokine-mediated chronic tissue degeneration comprising the step of administering a  
therapeutically effective amount, or a prophylactically effective amount, of the  
15   compound according to claim 1 or a pharmaceutically acceptable salt thereof.

                  26. A method of treatment or prevention of allergic rhinitis, allergic  
conjunctivitis, eosinophilic granuloma, osteoporosis, arterial restenosis,  
atherosclerosis, reperfusion injury of the myocardium chronic glomerulonephritis,  
20   vernal conjunctivitis, cachexia, transplant rejection, or graft versus host disease,  
comprising the step of administering a therapeutically effective amount, or a  
prophylactically effective amount, of the compound according to claim 1 or a  
pharmaceutically acceptable salt thereof.

25                   27. A method of treatment or prevention of depression, memory  
impairment, monopolar depression, Parkinson disease, Alzheimer's disease, acute and  
chronic multiple sclerosis, psoriasis, benign or malignant proliferative skin diseases,  
atopic dermatitis, urticaria, cancer, tumour growth or cancerous invasion of normal  
tissues, comprising the step of administering a therapeutically effective amount, or a  
30   prophylactically effective amount, of the compound according to claim 1 or a  
pharmaceutically acceptable salt thereof.

                  28. A method of enhancing cognition in a healthy subject comprising  
administering a safe cognition enhancing amount of compound of claim 1.

35

29. A method of enhancing cognition in a healthy subject comprising administering a safe, non-emetic, cognition enhancing amount of compound of claim 1.

30. A method of enhancing cognition in a healthy subject according to claim 28, wherein the healthy subject is a human 40 years of age or older.

31. A method of enhancing cognition in a healthy subject according to claim 28, wherein the healthy subject is a human 55 years of age or older.

32. Use of a compound of formula I, as defined in any one of claims 1 to 22, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament of treatment or prevention of asthma; chronic bronchitis; chronic obstructive pulmonary disease; adult respiratory distress syndrome; infant respiratory distress syndrome; cough; chronic obstructive pulmonary disease in animals; adult respiratory distress syndrome; ulcerative colitis; Crohn's disease; hypersecretion of gastric acid; bacterial, fungal or viral induced sepsis or septic shock; endotoxic shock; laminitis or colic in horses; spinal cord trauma; head injury; neurogenic inflammation; pain; reperfusion injury of the brain; psoriatic arthritis; rheumatoid arthritis; ankylosing spondylitis; osteoarthritis; inflammation; or cytokine-mediated chronic tissue degeneration.

33. Use of a compound of formula I, as defined in any one of claims 1 to 22, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament of treatment or prevention of allergic rhinitis, allergic conjunctivitis, eosinophilic granuloma, osteoporosis, arterial restenosis, atherosclerosis, reperfusion injury of the myocardium chronic glomerulonephritis, vernal conjunctivitis, cachexia, transplant rejection, or graft versus host disease.

34. Use of a compound of formula I, as defined in any one of claims 1 to 22, or a pharmaceutically acceptable salt thereof, in the manufacture of a



medicament of treatment or prevention of depression, memory impairment, monopolar depression, Parkinson disease, Alzheimer's disease, acute and chronic multiple sclerosis, psoriasis, benign or malignant proliferative skin diseases, atopic dermatitis, urticaria, cancer, tumour growth or cancerous invasion of normal tissues.

- 5                    35. A compound of formula I, as defined in any one of claims 1 to 22, or a pharmaceutically acceptable salt thereof, for use in medical therapy, such as defined in claims 25, 26 and 27.